Three techniques. One wrong choice can cost you six months and $500K. Here is the framework I use to pick the right approach for every life sciences AI use case.

As a product manager building 10+ GenAI products across clinical trials, MedTech, and BioPharma at HCLTech, I've had to make this decision repeatedly. Each time, the stakes are high - regulated industries don't forgive expensive pivots.

The Three Approaches, Explained Simply

Prompt Engineering is writing better instructions for an existing LLM. No model changes. You're working within the model's existing knowledge. Cost: nearly zero. Time: hours to days.

Retrieval Augmented Generation (RAG) connects the LLM to external data sources - your drug database, clinical guidelines, EHR data - at inference time. The model retrieves relevant context before generating a response. Cost: moderate (vector DB, embedding pipeline). Time: weeks.

Fine-Tuning retrains the model on your domain-specific data, permanently changing its weights. The model "learns" your domain. Cost: high ($1K-$50K+ in compute, plus data curation). Time: weeks to months.

When to Use Each: The Decision Framework

Start with Prompt Engineering When:

  • You're prototyping or validating a use case
  • The task relies on general knowledge the model already has
  • You need results today, not next quarter
  • The output format matters more than domain depth (summarization, reformatting, extraction)

Example: Generating patient-friendly summaries of clinical trial protocols. GPT-4 already knows medical terminology; you just need to instruct it on tone and reading level.

Use RAG When:

  • Accuracy depends on current, specific data (drug formularies, institutional protocols, recent guidelines)
  • You need source attribution - "which guideline says this?"
  • The knowledge base changes frequently
  • You need to ground responses in verified sources to reduce hallucination

Example: A clinical decision support tool that answers physician questions using your hospital's specific formulary and care pathways. The model needs to cite which protocol it's referencing.

Fine-Tune When:

  • The model needs to deeply understand domain-specific language patterns (medical abbreviations, clinical note shorthand)
  • You need consistent output formatting that prompt engineering can't reliably achieve
  • Inference cost matters at scale (fine-tuned smaller models can outperform prompted large models)
  • You have high-quality, curated training data

Example: An NLP model that extracts structured data from pathology reports. The language is highly specialized, and the extraction format must be precise and consistent.

The Hybrid Approach: What Production Systems Actually Use

In practice, most production life sciences AI systems combine approaches. The pattern I see working best:

  1. Fine-tune a base model on medical literature for domain language understanding
  2. Add RAG for real-time data retrieval (current guidelines, drug databases, patient-specific context)
  3. Use prompt engineering for task-specific instructions and output formatting

This layered approach gives you domain depth (fine-tuning) + current accuracy (RAG) + task flexibility (prompting).

Cost-Benefit Analysis for Life Sciences

Here's the decision matrix I use:

  • Prompt Engineering: $0-$1K setup, hours to deploy, good for prototyping and general tasks. Risk: inconsistency, no data grounding.
  • RAG: $5K-$50K setup, weeks to deploy, good for data-grounded Q&A and decision support. Risk: retrieval quality limits output quality.
  • Fine-Tuning: $10K-$100K+ setup, months to deploy, good for specialized language understanding and consistent extraction. Risk: data quality dependency, model drift.

Common Mistakes I've Seen

  • Fine-tuning when RAG would suffice. If your problem is "the model doesn't know about our specific drug database," that's a retrieval problem, not a training problem.
  • Skipping prompt engineering. Teams jump to fine-tuning without testing whether better prompts solve the problem. Always test prompting first.
  • Ignoring the regulatory implications. Fine-tuned models are harder to validate and explain to regulators. RAG systems with clear source attribution are easier to audit.
  • Underestimating RAG infrastructure. RAG isn't just "add a vector database." It requires chunking strategy, embedding model selection, retrieval ranking, and continuous index maintenance.

Key Takeaways

  • Always start with prompt engineering to validate the use case before investing in RAG or fine-tuning.
  • RAG is usually the right choice for clinical applications because it provides data grounding and source attribution.
  • Fine-tune only when you have clear evidence that domain language understanding is the bottleneck.
  • Production systems combine all three - fine-tuning for domain depth, RAG for current data, prompting for task control.
  • Regulatory considerations favor RAG over fine-tuning because retrieved sources are auditable.